You just read:

BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy

News provided by

BerGenBio ASA

Apr 02, 2019, 05:23 ET